For healthcare professionals only


England lags behind Scotland in assessing cancer drug

BMJ 2005; 331 doi: (Published 22 September 2005) Cite this as: BMJ 2005;331:652
  1. Roger Dobson
  1. Abergavenny

    The National Institute for Health and Clinical Evidence (NICE) is looking at ways to speed up the delivery of its guidance on the use of new drugs following complaints from charities, such as CancerBACUP (see above), and the achievement of faster approval times by a comparable body elsewhere in the UK.

    The Scottish Medicines Consortium, which fulfils the role of NICE in Scotland, appears able to assess drugs more quickly than its English counterpart. It has given its decision on the breast cancer …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription